SocialDiabetes
SocialDiabetes (Barcelona, founded 2012) is a CE-marked / MDR Class IIB certified digital health platform for type 1 and type 2 diabetes management, combining a patient-facing mobile app with a B2B medical platform for hospitals, pharma, and payers across Spain, Mexico, and the UK.
- Company typePrivate
- Founded2012
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What SocialDiabetes does
SocialDiabetes, S.L. is a Barcelona-based digital health company founded in 2012 by Víctor Bautista following his own diagnosis of type 1 diabetes. It operates a two-sided diabetes management platform: a consumer-facing mobile application (iOS and Android, first Android release January 2012) for people with type 1 and type 2 diabetes, paired with a B2B web-based medical platform for healthcare professionals. The proprietary Bolus Advisor (SmartBolusCalculator) recommends rapid insulin doses based on blood glucose, carbohydrate intake, and patient-specific sensitivity ratios; the platform synchronizes patient-registered data to the medical dashboard in real time, supports telemedicine via chat and video, and is compatible with over 90% of medical devices on the market — including commercial integrations with Dexcom, FreeStyle Libre, Menarini GlucoLog, Ascensia, Novo Nordisk's NovoPen, and Insulcheck, as well as open-source ecosystems xDrip+ and Nightscout. It holds CE marking under MDD 93/42/EEC, MDR Class IIB certification achieved in June 2025, US FDA Medical Device Establishment Registration, and UK MHRA registration, with data hosted on Google Cloud and GDPR-compliant APIs for user data portability.
The company monetizes through five streams: a freemium consumer app (premium subscription features); enterprise B2B subscription licensing of the medical platform to hospitals, clinics, and NHS trusts; multi-year regional contracts with pharmaceutical manufacturers (Sanofi Spain 2014, Sanofi MEX 2020, Sanofi LATAM 2022, Novo Nordisk Global 2023); payer/insurer partnerships (AXA Partners Mexico 2019, Sura Mexico 2023) for population management of metabolic syndrome patients; and device-integration agreements with manufacturers such as Menarini, Ascensia, and Dexcom Europe. Operations span Spain (Barcelona headquarters) and Mexico (regional HQ opened July 2019), with named enterprise customers including HM Hospitales, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Hospital del Mar, Complejo Hospitalario de Navarra, NHS England, NHS Scotland, Clínicas Cuidate, and Akademia Diabetes (a 2022 digital patient-education sub-brand). Total disclosed funding since founding sums to roughly €3.9M in grants and seed capital (including European Commission, EIT Health, ENISA, and NextGenerationEU funding), supplemented by a strategic equity investment from CAF (Development Bank of Latin America) through ALLVP's Venture Innovation Fund II in November 2020; the company remains privately held with headcount in the 11–50 band.
SocialDiabetes firmographics
Firmographics- Name
- SocialDiabetes
- Legal name
- SOCIALDIABETES, S.L.
- Website
- https://socialdiabetes.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SocialDiabetes (Barcelona, founded 2012) is a CE-marked / MDR Class IIB certified digital health platform for type 1 and type 2 diabetes management, combining a patient-facing mobile app with a B2B medical platform for hospitals, pharma, and payers across Spain, Mexico, and the UK.
- Ownership category
- akta.pro rank
SocialDiabetes industry classification
Industry- Product category
- Digital Diabetes Management Software
- NAICS
- Other Individual and Family Services (62419), Services for the Elderly and Persons with Disabilities (62412)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
- akta.pro secondary industries
- Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
Keywords
Where SocialDiabetes is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
SocialDiabetes business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Patient App Subscriptions: SocialDiabetes app is available for free download with basic features. Premium features are offered through a paid subscription model. The platform removed premium version restrictions and improved the medical platform while expanding connectivity.
- Healthcare Provider Platform Licensing: B2B licensing of the medical platform to hospitals, clinics, and healthcare providers for remote patient monitoring and telemedicine. During COVID-19, the platform was offered free for 6 months to centers to avoid saturation.
- Pharmaceutical Industry Partnerships: Contracts with pharmaceutical companies including Sanofi Spain (first contract 2014), Sanofi MEX (digitization patient program), and regional contracts with Sanofi LATAM. Partnerships involve patient engagement programs, treatment adherence solutions, and RWD for clinical trials.
- Insurance/Payer Partnerships: Partnerships with insurance companies like AXA Partners Mexico and Sura Mexico for population management and metabolic syndrome patient management, providing cost and risk control through big data analytics.
- Device Integration Partnerships: Agreements with medical device manufacturers (Menarini Diagnostics, Ascensia, Dexcom) that include commercial partnerships and potentially licensing fees for integration and data connectivity.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free App - Basic diabetes management features |
| Subscription | Monthly | Premium App Features |
| Subscription | Annual | Medical Platform for Healthcare Professionals |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels6 records
SocialDiabetes product offering
Product offeringCore offering
SocialDiabetes operates a cloud-based digital health platform consisting of a mobile app for people with type 1 and type 2 diabetes and a web-based Medical Platform for healthcare professionals. The system enables real-time data synchronization, insulin dose calculation via the proprietary Bolus Advisor (SmartBolusCalculator), telemedicine consultations, and integration with over 90% of medical devices on the market including CGMs, glucometers, and smart insulin pens. The platform is sold B2C as a freemium app and B2B as an enterprise remote patient monitoring solution to hospitals, pharmaceutical companies, and insurers.
Product overview
SocialDiabetes offers an integrated digital diabetes management ecosystem consisting of two primary products: the SocialDiabetes App (mobile application for patients) and the SocialDiabetes Medical Platform (web-based platform for healthcare professionals). These core products work together through data synchronization, enabling remote patient monitoring and telemedicine capabilities. Key features include the proprietary Bolus Advisor (SmartBolusCalculator) for insulin dose recommendations, personalized follow-up tools, and telemedicine chat/video functionality. The ecosystem is expanded through Akademia Diabetes (patient education platform), LogMeal AI (nutritional recognition), and integrations with major CGM devices (Dexcom, FreeStyle Libre), smart insulin pens, and health platforms (Apple Health). Research initiatives include artificial pancreas development and value-based care programs funded by EIT Health and EU NextGenerationEU grants.
Differentiator
Problem solved
Functional benefit
Brands
- Akademia Diabetes: The first digital diabetes education program focused on patient empowerment, launched in 2022.
Products and services
- SocialDiabetes App Mobile application for people with type 1 and type 2 diabetes to track blood glucose, count carbohydrates, calculate insulin doses via the SmartBolusCalculator, monitor physical activity, and synchronize data with healthcare providers. Available free on iOS App Store and Google Play with optional premium features via subscription.
- SocialDiabetes Medical Platform Web-based professional platform for healthcare providers to remotely monitor patients with diabetes in real time, manage patient data, generate alerts, conduct telemedicine consultations via chat and video, and make data-driven treatment decisions. Compatible with over 90% of medical devices on the market and used by hospitals, clinics, and healthcare networks across Europe and Latin America.
- Akademia Diabetes Digital diabetes education program focused on patient empowerment. Provides structured educational content to help people with diabetes build self-management knowledge and skills, available at akademiadiabetes.com.
Quantifiable outcome
- Average HbA1c of 6.7% for Type 1 users and 6.5% for Type 2 users with regular platform use
- +4 more outcomes
Companies that use SocialDiabetes
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles4 records
SocialDiabetes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability7 records
Feature7 records
SocialDiabetes partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and minor.
- Menarini DiagnosticscoreStart of commercial collaboration with Menarini Diagnostics in 2016. Integration with Menarini's GlucoLog WEB devices for blood glucose monitoring connectivity.
- Munich REcoreWinner of MunichRE InsurTech Accelerator 2016. Partnership for insurance technology solutions in diabetes management.
- Sanofi SpaincoreFirst pharmaceutical industry contract established in 2014. Sanofi Spain collaboration for diabetes management solutions and patient engagement programs.
- University of OxfordcoreSelected for educational project of the Government of Scotland in collaboration with Oxford University in 2017.
- University of GironacorePartnership established in 2021 for functional evolution based on Artificial Intelligence. Collaboration to develop AI algorithms based on Artificial Pancreas for MDI patients.
- FarmalistominorPartnership with Farmalisto, distributor of health services and medical devices in Latin America, established 2021.
- DexcomcoreIntegration partnership with Dexcom established 2020 (xDrip+ and Nightscout integration). Contract with Dexcom Europe for CGM integration signed in 2022.
- Novo NordiskcoreCollaboration with Novo Nordisk Global established 2022 for NovoPen integration. Full agreement signed in 2023.
- Akademia DiabetesminorAkademia Diabetes was born in 2022 as the first digital diabetes education program focused on patient empowerment.
- Air Liquide EspañaminorCommercial partnership established with Air Liquide España in 2023.
- AXA Partners MexicocorePartnership with AXA Partners Mexico established 2019 for insurance coverage of digital diabetes management.
- Mexican Diabetes AssociationminorCollaboration with Mexican Diabetes Association established 2020.
- Sura MexicominorAgreement with Sura Mexico for management of patients with metabolic syndrome established 2023.
- Hospital del Mar BarcelonaminorCollaboration agreement established in 2021 for diabetes management platform integration.
- Complejo Hospitalario de NavarraminorCollaboration agreement established in 2021 for platform integration.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
SocialDiabetes competitors and assessment
Company assessmentDirect peers
- mySugr (Roche Diabetes Care): mySugr is one of the most established diabetes self-management apps, now owned by Roche. It offers bolus calculation, logging, CGM integration and a medical device–style bolus advisor (accredited in EU), directly overlapping SocialDiabetes's core patient-facing product. Both target T1/T2 patients with freemium + premium models.
- Glooko: Glooko provides a unified diabetes data management platform that integrates with 95+ diabetes devices and offers remote patient monitoring for clinics — the same dual B2C/B2B positioning as SocialDiabetes. Direct overlap in device-agnostic interoperability and HCP-facing analytics.
- One Drop: One Drop is a US-based digital health company offering diabetes self-management with AI-driven predictions, coaching, and integrated devices. Targets the same T2 population with a direct-to-consumer subscription model and B2B payer partnerships — a near-mirror of SocialDiabetes's business model.
- DarioHealth: DarioHealth is a digital therapeutics platform spanning diabetes, hypertension and musculoskeletal conditions, with B2B payer and employer channels. Competes in the same RPM and chronic-condition digital therapeutic category where SocialDiabetes operates its medical platform.
- WellDoc (BlueStar): WellDoc's BlueStar was the first FDA-cleared mobile prescription therapy for Type 2 diabetes, positioned as a regulated digital therapeutic. Directly comparable to SocialDiabetes's MDR Class IIB Bolus Advisor — both sell clinically validated, regulated software for diabetes management to providers and payers.
- Voluntis (AstraZeneca): Voluntis (acquired by AstraZeneca) develops prescription digital therapeutics for chronic conditions including diabetes (Insulia) with insulin dose titration. Closely comparable regulated digital therapeutic positioning targeting the same T2 patient and provider workflows as SocialDiabetes.
Broad incumbents
- Dexcom (Dexcom Clarity): Dexcom is the leading CGM manufacturer and offers Clarity, a free data management and analytics app for its hardware users. While not SocialDiabetes's direct head-to-head (it is hardware-tied), Dexcom's deepening decision-support features compete for the same patient engagement and clinician analytics use cases.
- Abbott (FreeStyle Libre / LibreView): Abbott's FreeStyle Libre is the world's leading consumer CGM, paired with the LibreView and LibreLinkUp apps for patients and clinicians. Like Dexcom, it is a hardware-tied incumbent whose growing app features and AI-based insights compete with SocialDiabetes's bolus and analytics offering.
- Omada Health: Omada Health is a leading virtual chronic condition management platform (diabetes prevention, hypertension, weight management) sold primarily to employers and payers in the US. Competes in the same value-based, payer-channel chronic disease management space, though with a stronger US employer footprint.
- Vida Health: Vida Health offers a multi-condition virtual care platform (diabetes, hypertension, weight, mental health) with employer and payer contracts. Overlaps with SocialDiabetes's medical platform in providing chronic disease coaching and remote monitoring, particularly in payer/RPM distribution models.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
SocialDiabetes social profiles
Digital presenceSocialDiabetes compliance and trust
Trust signalCompliance5 records
SocialDiabetes financial estimates
Financial estimateRevenue estimate
Valuation estimate
SocialDiabetes leadership team
Management profileNumber of profiles
Profiles4 records
SocialDiabetes funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SocialDiabetes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SocialDiabetes
What does SocialDiabetes do?
SocialDiabetes operates a cloud-based digital health platform consisting of a mobile app for people with type 1 and type 2 diabetes and a web-based Medical Platform for healthcare professionals. The system enables real-time data synchronization, insulin dose calculation via the proprietary Bolus Advisor (SmartBolusCalculator), telemedicine consultations, and integration with over 90% of medical devices on the market including CGMs, glucometers, and smart insulin pens. The platform is sold B2C as a freemium app and B2B as an enterprise remote patient monitoring solution to hospitals, pharmaceutical companies, and insurers.
Is SocialDiabetes a public or private company?
SocialDiabetes is a private company. It is classified as venture growth investor backed and is currently operating.
When was SocialDiabetes founded?
SocialDiabetes was founded in 2012. It employs 11 to 50 people.
Where is SocialDiabetes based?
SocialDiabetes is headquartered in Barcelona, Spain, in the Europe region.
How does SocialDiabetes make money?
Five revenue lines are on record. Patient App Subscriptions are the primary driver. The others are healthcare Provider Platform Licensing, pharmaceutical Industry Partnerships, insurance/Payer Partnerships and device Integration Partnerships.
Who are SocialDiabetes's main competitors?
Direct peers on record are mySugr (Roche Diabetes Care), Glooko, One Drop, DarioHealth, WellDoc (BlueStar) and Voluntis (AstraZeneca). Broad incumbents are Dexcom (Dexcom Clarity), Abbott (FreeStyle Libre / LibreView), Omada Health and Vida Health.
Does SocialDiabetes have an API?
Yes. SocialDiabetes provides Application Programming Interfaces (APIs) that allow Users to access and export their personal data. The platform enables users to have universal access to their data without conditions or tolls, making their data available through APIs so that Users can use their data as they freely decide based on their ownership of them and the corresponding rights of exploitation within the limits established by Law. The platform uses Open Data principles and data portability features.
What industry is SocialDiabetes in?
SocialDiabetes's product category is Digital Diabetes Management Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLALAGAD, Endocrinology & Diabetes Telemedicine Platforms. Its NAICS code is 62419 and its SIC code is 8000.